Korean J Psychopharmacol.  2006 Mar;17(2):219-228.

Early Treatment Response of Bupropion SR in Smoking Cessation according to Genetic Polymorphism and Temperamental Characteristics

• Lee YS
• Kim SY
• Han DH
• Min KJ
• Na C

Abstract

OBJECTIVE
Bupropion is an antidepressant with proven efficacy for smoking cessation, however the response rate is some limited. With this background, the authors investigated the difference of early bupropion response in smoking cessation according to individual genetic polymorphism and temperamental characteristics. METHOD: Subjects were 113 Korean male volunteers who were nicotine dependent and wanted to quit smoking. Authors compared 6 candidate genes (DRD2, DRD4, dopamine transporter, norepinephrine transporter, serotonin transporter, COMT), and Temperament Character Inventory (TCI) between response group and non-response group after 3 weeks bupropion treatment. RESULT: Among 6 candidate genes, DRD2 homozygotes (A2/A2+A1/A1), COMT H/H genotype and H allele carriers showed high rate of smoking cessation by bupropion. NET-8 GG genotype and G allele carriers showed low rate of smoking cessation by bupropion. Persistence score in TCI was significant between two groups.
CONCLUSION
DRD2, COMT, NET-8 genetic polymorphisms and some temperamental characteristics could predict success of smoking cessation by early treatment response of bupropion.

Keyword

Bupropion; Smoking cessation; Genetic polymorphism; Temperamental characteristics

MeSH Terms

Alleles
Bupropion*
Dopamine Plasma Membrane Transport Proteins
Genotype
Homozygote
Humans
Male
Nicotine
Norepinephrine Plasma Membrane Transport Proteins
Polymorphism, Genetic*
Serotonin Plasma Membrane Transport Proteins
Smoke*
Smoking Cessation*
Smoking*
Temperament*
Volunteers
Bupropion
Dopamine Plasma Membrane Transport Proteins
Nicotine
Norepinephrine Plasma Membrane Transport Proteins
Serotonin Plasma Membrane Transport Proteins
Smoke